SI1569679T1 - Imunosupresija s šaperoninom 10 - Google Patents

Imunosupresija s šaperoninom 10

Info

Publication number
SI1569679T1
SI1569679T1 SI200331912T SI200331912T SI1569679T1 SI 1569679 T1 SI1569679 T1 SI 1569679T1 SI 200331912 T SI200331912 T SI 200331912T SI 200331912 T SI200331912 T SI 200331912T SI 1569679 T1 SI1569679 T1 SI 1569679T1
Authority
SI
Slovenia
Prior art keywords
donor
recipient animal
cpn10
administration
host disease
Prior art date
Application number
SI200331912T
Other languages
English (en)
Slovenian (sl)
Inventor
Geoffrey R Hill
Tatjana Banovic
Halle Morton
Alice Christina Cavanagh
Original Assignee
Cbio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cbio Ltd filed Critical Cbio Ltd
Publication of SI1569679T1 publication Critical patent/SI1569679T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200331912T 2002-11-06 2003-11-06 Imunosupresija s šaperoninom 10 SI1569679T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2002952492A AU2002952492A0 (en) 2002-11-06 2002-11-06 Chaperonin 10 immunosuppression
EP03769073A EP1569679B1 (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression
PCT/AU2003/001467 WO2004041300A1 (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression

Publications (1)

Publication Number Publication Date
SI1569679T1 true SI1569679T1 (sl) 2011-01-31

Family

ID=28795882

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331912T SI1569679T1 (sl) 2002-11-06 2003-11-06 Imunosupresija s šaperoninom 10

Country Status (16)

Country Link
US (3) US7618935B2 (enExample)
EP (3) EP2255824B1 (enExample)
JP (2) JP4716731B2 (enExample)
KR (1) KR101088740B1 (enExample)
CN (1) CN100525832C (enExample)
AT (1) ATE489963T1 (enExample)
AU (1) AU2002952492A0 (enExample)
CA (1) CA2505141C (enExample)
CY (1) CY1110972T1 (enExample)
DE (1) DE60335202D1 (enExample)
DK (1) DK1569679T3 (enExample)
ES (1) ES2351993T3 (enExample)
NZ (1) NZ540433A (enExample)
PT (1) PT1569679E (enExample)
SI (1) SI1569679T1 (enExample)
WO (1) WO2004041300A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517808A (ja) 2004-01-16 2007-07-05 キュビオ リミテッド Ｔｏｌｌ様受容体誘導性のサイトカインおよびケモカイン分泌のシャペロニン１０調節
AU2005204979B2 (en) * 2004-01-16 2010-10-21 Cbio Limited Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
US8036710B2 (en) * 2004-05-07 2011-10-11 Qualcomm, Incorporated Power-efficient multi-antenna wireless device
AU2006269824B2 (en) * 2005-07-11 2012-04-19 Cbio Limited Chaperonin 10-induced immunomodulation
EP1906989A4 (en) 2005-07-11 2009-08-19 Cbio Ltd IMMUNOMODULATION INDUCED BY CHAPERONIN 10
EP2463307A1 (en) 2005-08-31 2012-06-13 CBIO Limited Modified chaperonin 10
AU2006303826B2 (en) * 2005-10-20 2012-07-19 Cbio Limited Treatment of hypersensitivity
CA2626692A1 (en) * 2005-10-20 2007-04-26 Cbio Limited Treatment of hypersensitivity
MX2008011167A (es) 2006-03-02 2008-11-12 Cbio Ltd Regulaciòn de respuestas inmunes mediante la modulaciòn de la funciòn de cèlulas presentadoras de antìgenos.
CA2720617A1 (en) * 2008-04-11 2009-10-15 Cbio Limited Modified cpn10 and prr signalling
US20110243921A1 (en) * 2010-03-30 2011-10-06 Cbio Limited Prevention and treatment of cutaneous lupus erythematosus
WO2013158959A1 (en) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of graft-versus-host disease
WO2014063194A1 (en) 2012-10-23 2014-05-01 The University Of Sydney Elastic hydrogel
US10842913B2 (en) 2012-12-10 2020-11-24 Allergan Pharmaceuticals International Limited Scalable three-dimensional elastic construct manufacturing
RU2677637C2 (ru) 2013-08-13 2019-01-18 Эластаджен Пти Лтд Регенерация поврежденной ткани

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2176948C (en) * 1993-11-30 2007-05-15 Halle Morton Chaperonin 10
WO1995015338A1 (en) 1993-11-30 1995-06-08 The University Of Queensland Chaperonin 10
US5989804A (en) * 1994-07-08 1999-11-23 New England Medical Center Hospitals, Inc. E6 binding proteins
EP0845994A1 (en) * 1995-08-09 1998-06-10 Schering Corporation Combined use of interleukin-10 and cyclosporin for immunosuppression therapy
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
EP1218030A4 (en) 1999-09-10 2004-09-15 Univ Fordham METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING TRANSPLANT REJECTION BY USING HEAT SHOCK PROTEINS
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method

Also Published As

Publication number Publication date
CN1735428A (zh) 2006-02-15
US20120082690A1 (en) 2012-04-05
EP1569679A4 (en) 2008-02-27
EP2255824B1 (en) 2014-07-23
EP1569679B1 (en) 2010-12-01
DK1569679T3 (da) 2011-01-10
JP4716731B2 (ja) 2011-07-06
AU2002952492A0 (en) 2002-11-21
EP2255824A1 (en) 2010-12-01
ES2351993T3 (es) 2011-02-14
US7618935B2 (en) 2009-11-17
KR101088740B1 (ko) 2011-12-01
CA2505141A1 (en) 2004-05-21
WO2004041300A1 (en) 2004-05-21
PT1569679E (pt) 2010-12-14
ATE489963T1 (de) 2010-12-15
EP2818179A1 (en) 2014-12-31
CY1110972T1 (el) 2015-06-11
US8067361B2 (en) 2011-11-29
US20060198834A1 (en) 2006-09-07
NZ540433A (en) 2008-03-28
KR20050086428A (ko) 2005-08-30
DE60335202D1 (en) 2011-01-13
US20100099605A1 (en) 2010-04-22
CN100525832C (zh) 2009-08-12
CA2505141C (en) 2012-07-17
JP2006508099A (ja) 2006-03-09
EP1569679A1 (en) 2005-09-07
JP2011088920A (ja) 2011-05-06

Similar Documents

Publication Publication Date Title
CY1110972T1 (el) Ανοσοκαταστολη με σαπερονινη 10
EP1487431A4 (en) PREVENTING AND / OR TREATING CARDIOVASCULAR DISEASE AND / OR RELATED CARDIAC INSUFFICIENCY
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
EP1688425A3 (en) Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases
BR0203650A (pt) Estentor de auto-articulação
WO2004028243A3 (en) Porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase
ES2114888T3 (es) Tratamiento contra el rechazo en el transplante de organos.
DE69426304D1 (de) Methoden zur regulation der den magen und darm betreffenden motilitaet
GB2357969A (en) Improvements in or relating to the treatment of lesions
DE69839696D1 (de) Anellierte dihydropyrane
BR9612821A (pt) Métodos para a prevenção de rejeição de enxerto em transplante e para a produção de uma célula de hospedeiro para terapia genética universal
PL327335A1 (en) Preserving solution
SI1567171T1 (sl) Uporaba dekstran sulfata za zdravljenje IBMIR
HU901516D0 (en) The use of s-adenosile-methionine in the treatment of pancreatitis, and in preventing the natural rejection of transplanted pancreas
DE3875306D1 (de) Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
PT1107789E (pt) Composições e métodos para proteger órgãos, tecidos e células de danos mediados pelo sistema imunitário
WO2005041877A3 (en) Method of inhibiting rejection following organ transplantation
MXPA05004121A (es) Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
DE60023034D1 (en) Cd45 hemmer
BG104258A (en) 4-cyano-4-deformylsordarin derivatives
MD980129A (en) Antiherpetic remedy
UA85060C2 (ru) Биологически активная добавка к пище
HUP0103107A2 (hu) Allogénikus és xenogénikus T-sejtek ex vivo kezelése gp39 antagonistákkal
of Man An act (Chapter No. 3) to prohibit commercial dealings in human organs intended for transplanting; to prohibit the transplanting of such organs between persons who are not genetically related; and for connected purposes. Dated 16 March 1993.(The Human Organ Transplants Act 1993)
NO20016326L (no) Anvendelse av proteinet UK 114 for å hindre avstötning av organtransplantatet